Christopher Wolfe, OD

speaker
205 appearances 1 recordings 1 series first heard May 2026 last heard 18 May

Christopher Wolfe, OD’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months
1 · May OctJan 26AprJulnow

Recordings per month over the last 12 months — 1 in all, peaking in May 2026 with 1.

Appearances

newest first · ▶ plays the moment
Our primary value is, hey, that patient who has diabetes in front of me that is struggling with their A1C, and now we see that they've got retinal hemorrhages and telangiectetic vessels, that I can actually show them that, and I can help them reinforce that.
And oh, by the way, I also know that they're at greater risk for glaucoma, and they're at greater risk for macular degeneration, and they're at greater risk for neurotrophic keratitis and dry eye, and I'm the best person to manage all of those things.
And that's kind of, I think, the identity that I'd love for us to be able to embrace more.
I think, Kirsten, one of the things that kind of strikes me is first, we got to have you back on the podcast.
The second thing is, if you're unpacking, if I'm a doctor, and I think one of the most compelling things, I'm going to say it this way, is you don't have to have a talk track to a patient if you fully understand what you're doing and you fully believe in what you're doing.
And so if I wanted to gain kind of an expertise to the level that you have and a sort of belief that this is absolutely the right thing, maybe I'm kind of there, but I need to dig a little bit more on my own.
Where would you say doctors should start?
Like, is there a place I can go to say, like, I'm going to unpack some of these studies so that, you know, maybe I'll read the abstract.
Maybe it'll pique my interest.
But, like, how do I get, you know, sort of the compelling storytelling that you have related to this in a way that's meaningful for my patients?
That's true.
We're going to have to do another episode on that.
Yeah, I think the other thing that you hit on, Erin, is that we all clamor to try to buy the new widget.
And we could probably spend a whole lot less money.
Not that widgets are bad, but we could spend a whole lot less money with, you know, 30 minutes every now and then trying to hop on and dive a little bit deeper into the newest research related to, you know, something like this to be able to talk to our patients about to still deliver a different experience that is just as valuable, if not more valuable to the patient.
So,
Kirsten, thanks so much for coming on.
This was a huge pleasure for me.
It's been great to not have to talk to John Nolan again about these things.
He's finally let somebody else talk to us about them.
Showing 161–180 of 205 · page 9 of 11 ← Previous Next →